ClinicalTrialsFinder
RecruitingPhase 1Phase 2NCT04691817

Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

A Phase Ib-II Trial of Tocilizumab and Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

Sponsor

Abramson Cancer Center at Penn Medicine

Enrollment

28 participants

Start Date

Jul 25, 2023

Study Type

INTERVENTIONAL

Conditions

Lung Cancer, Nonsmall Cell

Summary

This is a research study to evaluate the safety and effectiveness of tocilizumab in combination with atezolizumab to treat non-small cell lung cancer.

Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older
  • Prior exposure to at least 1 line of therapy
  • Exposure to a including checkpoint inhibitor in line of therapy immediately prior to enrollment on trial
  • ECOG PS 0-2

Exclusion Criteria7

  • Presence of a driver mutation that is susceptible to targeted therapy
  • No greater than CTCAE v5 grade 3 toxicity attributed to prior immunotherapy
  • Other active invasive malignancy requiring ongoing therapy
  • Evidence of progressing or untreated brain metastases
  • Evidence or history of leptomeningeal disease
  • Uncontrolled tumor related pain
  • History of an autoimmune disease or IPF

Interventions

DRUGAtezolizumab

1200mg infusion

DRUGTocilizumab

Tocilizumab 6mg/kg or 4mg/kg infusion

Locations(1)

Abramson Cancer Center of the University of Pennsylvania

Philadelphia, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04691817

Related Trials

Prospective Data Collection Initiative on Thoracic Malignancies

NCT0699624910 locations

Immunonutrition for Improving the Efficacy of Immunotherapy in Patients With Metastatic Non-small Cell Lung Cancer

NCT053848731 location

A Multicenter Cancer Biospecimen Collection Study

NCT045101291 location

ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC

NCT064265111 location

Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy

NCT066671541 location